UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | April 5, 2006 |
AVALON PHARMACEUTICALS, INC.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 001-32629 | 52-2209310 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 20358 Seneca Meadows Parkway, Germantown, Maryland | | 20876 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 301-556-9900 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(d) This amendment to the Current Report on Form 8-K of Avalon Pharmaceuticals, Inc. (the "Company") filed on February 23, 2006 is being filed to report that Mr. William H. Washecka, previously announced as being appointed to the Company's board of directors, was appointed on April 5, 2006 as a member and Chairman of the Company's Audit Committee. In connection with the appointment of Mr. Washecka to the Audit Committee, the Company's board of directors determined that Mr. Washecka is an "audit committee financial expert" as defined by the Securities and Exchange Commission (the "SEC").
Except as noted herein, the Company’s Current Report on Form 8-K remains as originally filed with the SEC on February 23, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | AVALON PHARMACEUTICALS, INC. |
| | | | | |
| April 5, 2006 | | By: | | /s/ Kenneth C. Carter, Ph.D.
|
| | | | |
|
| | | | | Name: Kenneth C. Carter, Ph.D. |
| | | | | Title: President and CEO |
